Vol.6, 2024 YAFO Weekly Global Wrap-up Report 雅法全球生物医药交易周报

2024-02-19

1. Summary of the week

Over the China Spring Festival, from February 8 to 18, 2024, there is 1 in-licensing agreement that was signed between VBI Vaccines and Brii Biosciences for 3 assets namely BRII-179 (VBI-2601), PreHevbri, and VBI-1901. This agreement involved the transfer of manufacturing technologies for BRII-179 and PreHevbrio/PreHevbri to more manufacturing facilities, thereby extending the reach for global commercial distribution. Furthermore, securing the rights to VBI-1901 in the APAC Region (excluding Japan) creates fresh opportunities in the Asia-Pacific Area.

While on the global setting, there are 12 licensing and cooperation agreements signed. The BioNTech and Autolus Strategic CAR-T Cell Therapy Collaboration top this week’s deals with $50 million upfront payment.

春节期间（ 2024 年 2 月 8 日至 18 日），中国市场仅有一件交易。VBI Vaccines 和腾盛博药签署了一项许可协议，涉及三项资产，分别是 BRII-179 (VBI-2601)、PreHevbri® 和 VBI-1901。该协议涉及将 BRII-179 和 PreHevbrio/PreHevbri 的制造技术转移到更多制造设施，从而扩大全球商业分布范围。此外，腾盛博药还获得 VBI-1901 在亚太地区（除日本外）的权利，为亚太地区创造了新的机会。同时，在全球范围内，共有 12 项许可和合作协议达成。其中，BioNTech 和 Autolus 的战略性 CAR-T 细胞疗法合作在本周的交易中排名首位，首付款达 5000 万美元。

2. Licensing Deals

2a. China section

2b. Global section

3. M&A Deals

4. Top Deals of the year 2024

5. 2019-2023 China Innovative Drug Licensing Transactions

About YAFO Capital

Founded in 2013, YAFO Capital is a Shanghai-based boutique investment and advisory firm, with a professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross-border licensing transactions in the past three years. For more information, please visit http://www.yafocapital.com

雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。

ACCESS CHINA